A5061066145- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Gallbladder and Bile Duct Disorders
- Prostate Cancer Treatment and Research
- Gastric Cancer Management and Outcomes
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- CAR-T cell therapy research
- Metastasis and carcinoma case studies
- Advanced Radiotherapy Techniques
- Renal cell carcinoma treatment
- Chronic Lymphocytic Leukemia Research
- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cutaneous lymphoproliferative disorders research
- Multiple and Secondary Primary Cancers
- Colorectal Cancer Treatments and Studies
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Viral-associated cancers and disorders
- Lung Cancer Research Studies
- Gastrointestinal Tumor Research and Treatment
- Head and Neck Cancer Studies
Emory University
2018-2025
Winship Cancer Institute
2018-2024
Cancer Institute (WIA)
2024
Piedmont Cancer Institute
2018-2023
University of Rochester
2023
Emory University Hospital
2023
Philadelphia College of Osteopathic Medicine
2022
University of Miami
2022
Kent State University
2013
Abstract Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. However, the prognostic implication +1q not evaluated setting standard triplet regimens. We retrospectively analyzed 201 consecutive patients newly diagnosed who received induction lenalidomide, bortezomib, dexamethasone (RVD) were tested for at diagnosis by fluorescent in-situ hybridization. Patients ( n = 94), compared to those without 107), had shorter median...
BACKGROUND. MEK inhibitors have limited activity in biliary tract cancers (BTCs) as monotherapy but are hypothesized to enhance responses programmed death ligand 1 (PD-L1) inhibition.
Acquired resistance is inevitable in non–small cell lung cancers (NSCLCs) treated with osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 promoted downstream oncogenic signaling EGFR-mutated (EGFRMT) NSCLC cells OSI, suggesting a role for activation OSI resistance. Indeed, treatment MRX-2843, first-in-class kinase inhibitor, resensitized GAS6-treated to OSI. Both EGF stimulated PI3K/AKT MAPK/ERK parental cells, but only activated these pathways OSI-resistant...
Immune checkpoint inhibitor (ICI) therapy is highly effective in metastatic mismatch repair-deficient (MMR-D) colorectal cancer (CRC). In this study, we evaluated molecular and clinical predictors of ICI response MMR-D CRC.
Background Immune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). Biomarkers for mRCC patients treated with ICI are limited, and body composition is underutilized in mRCC. We investigated association between clinical outcomes ICI-treated patients. Methods performed a retrospective analysis 79 at Winship Cancer Institute from 2015-2020. Baseline CT images were collected mid-L3 segmented using SliceOMatic v5.0 (TomoVision). Density...
Although an expanding array of effective treatments has resulted in recent improvement survival patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification prognostic factors remains a priority. We assessed the impact time to progression disease (POD) after first-line therapy among 455 relapsed MCL. Patients were categorized by duration first remission as PRF/POD6, defined progressive during induction or POD within 6 months diagnosis (n = 65; 14%); POD6-24,...
Immune checkpoint inhibitors (ICIs) are an important treatment for metastatic renal cell carcinoma (mRCC). These agents may cause immune-related adverse events (irAEs), and the relationship between irAEs outcomes is poorly understood. We investigated association clinical in patients with mRCC treated ICIs.We performed a retrospective study of 200 ICIs at Winship Cancer Institute from 2015 to 2020. Data on were collected clinic notes laboratory values grades determined using Common...
To report the activity of venetoclax in patients with relapsed mantle cell lymphoma (MCL), we identified 81 treated monotherapy (n = 50, 62%) or combination a Bruton tyrosine kinase inhibitor (BTKi) 16, 20%), an anti-CD20 monoclonal antibody 11, 14%), other active agents at 12 US academic medical centers. Patients had high-risk disease features including Ki67 >30% (61%), blastoid/pleomorphic histology (29%), complex karyotype (34%), and TP53 alterations (49%), received median 3 prior...
Several immune checkpoint inhibitors (ICIs) are approved for the treatment of advanced urothelial carcinoma (UC). There limited biomarkers ICI-treated patients with UC. We investigated association between body composition and clinical outcomes in UC patients.We conducted a retrospective analysis 70 at Winship Cancer Institute from 2015 to 2020. Baseline computed tomography images within 2 months ICI initiation were collected mid-L3 muscle fat compartments (subcutaneous, intermuscular,...
Abstract Objective Complex ablative maxillary and mandibular defects often require osseous free flap reconstruction. Workhorse options include the fibula, scapula, osteocutaneous radial forearm (OCRFF). The choice of donor site for harvest should be driven not only by reconstructive goals but also morbidity. goal this study is to evaluate long‐term postoperative musculoskeletal morbidity at after harvest. Study Design Cohort cross‐sectional analysis. Methods A retrospective review patients...
ABSTRACT Objectives The 2012 United States Preventive Services Task Force (USPSTF) Grade D recommendation against prostate‐specific antigen (PSA) screening has resulted in a shift to higher‐stage prostate cancer (PC) at diagnosis. We evaluate the utilization of radical prostatectomy (RP) versus radiation therapy (RT) US for Gleason grade group 5 (GG5) before and after 2012. Methods identified 34,011 men with localized GG5 PC undergoing primary (1) RP or (2) RT + androgen deprivation (ADT)...
326 Background: Fluciclovine PET-guided prostate cancer (PCa) radiotherapy (XRT) improves failure-free survival (FFS) over conventional imaging (CI) alone in post-prostatectomy (RRP) recurrence (EMPIRE-1, PMID: 33971152). In this randomized trial we explored dose-escalation (DE) to sites of PET uptake (not done EMPIRE-1) using either fluciclovine or 68 GaPSMA PET/CT-guided XRT and compared control the arm EMPIRE-1 2Y failure free 79.6%. Methods: From 2019-2023, 140 pts w/ PCa with detectable...
Statin drugs, frequently used to treat hyperlipidemia, are associated with improved survival outcomes in multiple solid tumor types, including head and neck squamous cell carcinoma (HNSCC). Preclinical studies suggest that manipulation of cholesterol statins other agents can enhance the function components involved anti-tumor immune responses. Retrospective types statin therapy is responses checkpoint blockade (ICB), but this has not yet been investigated HNSCC. Pharmacy records were...
Abstract Clinical outcomes and predictors of survival in patients with newly diagnosed mantle cell lymphoma (MCL) treated the rituximab era (2000–2015) at 12 US academic centers were assessed to identify determinants across age groups. Objectives characterize compare practice patterns, prognostic factors for younger (age < 65) older ≥ 65 years). Among 1162 included, 697 465 older. In patients, 2‐year progression free (PFS) overall (OS) rates 79% 92% respectively; blastoid histology, ECOG...
BACKGROUND Proton therapy may reduce cognitive deficits after radiotherapy among brain tumor survivors, although current data are limited to retrospective comparisons between historical cohorts. The authors compared intelligence quotient scores within a case‐matched cohort of children with medulloblastoma treated proton radiation (PRT) or photon (XRT) over the same time period. METHODS Among 88 consecutive patients standard‐risk PRT XRT at 2 institutions from 2000 2009, 50 were matched 1:1...
In advanced urothelial cancers (UC), immune checkpoint inhibitors (ICI) show promise as a durable therapy. Immune-related adverse events (irAEs), side effect of ICIs, may serve an indicator beneficial response. We investigated the relationship between irAEs and clinical outcomes in patients with UC who received ICI.In this retrospective study, we 70 treated ICIs at Winship Cancer Institute from 2015 to 2020. Data on were collected through chart review. Cox's proportional hazard model...
Background To the authors' knowledge, race‐based differences in efficacy for treatment of patients with advanced non–small cell lung cancer (NSCLC) have not been studied to date due underrepresentation minority backgrounds pivotal trials. In current study, authors examined real‐world outcome a diverse patient population. Methods The retrospectively analyzed clinical outcomes NSCLC who were treated single‐agent immune checkpoint blockade (ICB) between 2013 and July 2018 at Winship Cancer...
Imaging with novel PET radiotracers has significantly influenced radiotherapy decision making and radiation planning in patients recurrent prostate cancer (PCa). The purpose of this analysis was to report the final results for management changes based on <sup>18</sup>F-fluciclovine PET/CT findings determine whether change trend remained after completion accrual. <b>Methods:</b> Patients detectable prostate-specific antigen (PSA) prostatectomy were randomized undergo either conventional...
Enhancing the efficacy of immunotherapy in brain metastases (BrM) requires an improved understanding immune composition BrM and how this is affected by radiation dexamethasone. Our two-arm pilot study (NCT04895592) allocated 26 patients with to either low (Arm A) or high B) dose peri-operative dexamethasone followed pre-operative stereotactic radiosurgery (pSRS) resection (n= 13 per arm). The primary endpoint, a safety analysis at 4 months, was met. secondary clinical endpoints overall...